Mar 17, 2022, 12:27 PM by

Mar 17, 2022, 12:27 PM by

Decentralized Clinical Trial Platform Provider Welcomes 100th Teammate

Mar 17, 2022, 12:27 PM by

Tesis Biosciences Partners with Frontier Management to Provide Exclusive Pharmacogenetic Testing for Residents of Frontier’s Senior Living Facilities

Mar 17, 2022, 12:27 PM by

Cloud-based software platform PubHive Navigator now supports auto-scheduling of aggregate safety reports plus bulk assignments of responsible report owners

Mar 17, 2022, 12:27 PM by

physIQ, a pioneer in digital medicine, and CellCarta, a global leader in precision medicine services, announce a strategic collaboration to undertake a groundbreaking study with the potential to revolutionize vaccine development.

Mar 17, 2022, 01:00 AM by User Not Found

Bio-IT World | The Bio-IT World Conference & Expo kicks off the first week in May, back in its pre-pandemic Spring timeslot. We are looking forward to joining the Bio-IT community both in person and virtually and exploring the progress the community has made over the past two years. While the program is packed full of sessions to flag, here are the sessions outside of the track schedule that we are highlighting

Mar 15, 2022, 15:27 PM by User Not Found

Bio-IT World | Element Biosciences has launched the Element AVITI System, a benchtop sequencer offering an unrivaled combination of performance, cost, and flexibility. Element’s proprietary Avidity Sequencing chemistries enable exceptional accuracy and cost efficiency that is unmatched by other benchtop systems, according to the company.

Mar 11, 2022, 14:10 PM by

Curebase and CoBTeK (team from Côte d’Azur) to Collaborate on a European Clinical Trial of Remote Tools Designed to Help Seniors Retain Autonomy

Mar 11, 2022, 14:09 PM by

MicrobioSeq represents the microbial genomics division of CD Genomics, headquartered in New York, USA. CD Genomics MicrobioSeq is committed to delivering comprehensive microbial solutions to human health, agriculture, the environment, and industry by characterizing microbiomes and leveraging microorganisms. The company has recently announced the launch of PCR-based microbial antibiotic resistance gene analysis service to help researchers develop new antimicrobial medicines to address the worldwide threat of antibiotic resistance.

Mar 11, 2022, 14:09 PM by

Mar 11, 2022, 14:09 PM by

As a reliable computational biology service provider based in New York, CD ComputaBio has recently launched homology modeling service to help researchers deeply understand the structure-activity relationship of the target protein, and provide strong support for structure-based rational drug design, protein function research, and protein engineering research. Relying on its professional team and advanced technology, as well as high-quality products and services, CD ComputaBio has gained a solid reputation.

Mar 11, 2022, 14:09 PM by

CD ComputaBio, a reliable computational biology service provider located in New York, always hammers at researches and trials in order to provide customers with access to the latest software, technologies, and expertise at a competitive price and fast turnaround time. Recently, the product manager announced the launch of molecular docking service, which has a wide range of applications in the field of enzymology research and drug design.

Mar 11, 2022, 14:09 PM by

Mar 11, 2022, 14:09 PM by

Firstsource Solutions Limited, a global provider of Business Process Management (BPM) services and an RP-Sanjiv Goenka Group company, was ranked #1 in the 2022 Best in KLAS®: Software & Services Report, and noted as a leader in the Eligibility and Enrollment Services category.

Mar 11, 2022, 14:09 PM by

Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy

Mar 11, 2022, 14:09 PM by

A research team led by Samuel Beck, Ph.D., of the MDI Biological Laboratory in Bar Harbor, Maine, has identified disruption of chromatin architecture as the mechanism underlying inflammaging, a chronic, low-grade inflammatory response that has been linked to the chronic diseases of old age, including Alzheimer’s, cancer, diabetes, heart disease, macular degeneration and more, as well as to a shortened lifespan.

Mar 11, 2022, 14:09 PM by

Rho, a global full-service contract research organization (CRO), is sharing its drug development success and expertise in gene therapy research during the 5th Annual Gene Therapy for Rare Disorders Conference, taking place in Boston, Massachusetts from March 7-10. Rho’s Associate Director of Regulatory Strategy, Joseph Watson, Senior Director of Nonclinical Development, Brenda Faiola, and Research Scientist Kelsey Behrens will be giving a presentation titled, “Nonclinical Considerations to Enable a Successful Clinical Program.” The March 9 presentation at 2:00 p.m. will discuss key design and execution components, for nonclinical studies, necessary to enable clinical studies. The following items will be addressed: ü Considerations for gene therapy programs regarding animal models, dose selection, and delivery device compatibility ü Lessons Rho has learned in interacting with the FDA across various gene therapy programs ü Gene therapy approval examples that highlight key nonclinical considerations

Mar 11, 2022, 14:09 PM by

Mar 11, 2022, 14:09 PM by

Mar 11, 2022, 14:08 PM by